CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $1.58B, above the global median of $520.53M
- FinancialsAltman Z-Score 3.31: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
5.96BCNY885.64M · vs all stocks (USD)
Trailing P/E
43.48xRevenue (TTM)
10.64BCNY1.58B · vs all stocks (USD)
Profit Margin
1.34%Beta
0.0390xvs all stocks
52-Week Change
24.18%vs all stocks
Market Capitalization
5.96BCNY885.64M · vs all stocks (USD)
Enterprise Value
6.22BCNY924.72M · vs all stocks (USD)
Trailing P/E
43.48xForward P/E
18.12xPrice to Sales (TTM)
0.5926xPrice to Book (MRQ)
2.04xEnterprise to Revenue
0.5850xEnterprise to EBITDA
24.19xGross Margin
8.12%Profit Margin
1.34%Operating Margin
2.17%Return on Assets (TTM)
2.13%Return on Equity (TTM)
4.70%Revenue (TTM)
10.64BCNY1.58B · vs all stocks (USD)
Revenue per Share (TTM)
18.34CNYUpdated Aug 20, 2026Quarterly Revenue Growth
4.10%Gross Profit (TTM)
869.99MCNY129.38M · vs all stocks (USD)
EBITDA (TTM)
335.51MCNY49.89M · vs all stocks (USD)
Net Income (TTM)
142.26MCNY21.16M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
21.70%Operating Cash Flow (TTM)
8.78MCNY1.31M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-26.03MCNY-3.87M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
-42.76KCNYFY2025 · Dec 31, 2025Revenue
10.38BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
9.52BCNYFY2025 · Dec 31, 2025Gross Profit
854.06MCNYFY2025 · Dec 31, 2025Operating Income
290.45MCNY43.19M · vs all stocks (USD)
Pre-tax Income
189.54MCNYFY2025 · Dec 31, 2025Income Tax Expense
55.70MCNYFY2025 · Dec 31, 2025Net Income
133.84MCNYFY2025 · Dec 31, 2025EBIT
214.02MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
335.51MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
121.14MCNYFY2025 · Dec 31, 2025Other Operating Expenses
39.34MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.05MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
24.48MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2308CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2308CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
579.90MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
579.90MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
133.84MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-21.00CNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
179.58MCNYFY2025 · Dec 31, 2025Free Cash Flow
162.56MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.19BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
133.84MCNYFY2025 · Dec 31, 2025Other Non-cash Items
28.39MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
163.19MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-145.84MCNYFY2025 · Dec 31, 2025Capital Expenditures
-17.02MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-17.02MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
790.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-840.60MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-20.08MCNYFY2025 · Dec 31, 2025Other Financing Charges
-42.50MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-113.18MCNYFY2025 · Dec 31, 2025Shares Outstanding
579.89MSharesUpdated Aug 20, 2026Float Shares
147.12MSharesUpdated Aug 20, 2026% Held by Insiders
75.27%vs all stocks
% Held by Institutions
0.53%vs all stocks
Total Cash (MRQ)
762.20MCNY113.35M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.31CNYUpdated Aug 20, 2026Total Debt (MRQ)
769.89MCNY114.49M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2487xCurrent Ratio (MRQ)
1.71xBook Value per Share (MRQ)
5.34CNYUpdated Aug 20, 2026Total Assets
7.17BCNY1.07B · vs all stocks (USD)
Total Current Assets
6.69BCNYFY2025 · Dec 31, 2025Total Liabilities
4.16BCNYFY2025 · Dec 31, 2025Total Non-current Assets
481.72MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
145.02MCNYFY2025 · Dec 31, 2025Total Current Liabilities
4.01BCNYFY2025 · Dec 31, 2025Cash
1.19BCNYFY2025 · Dec 31, 2025Cash Equivalents
47.06MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.24BCNYFY2025 · Dec 31, 2025Accounts Receivable
3.85BCNYFY2025 · Dec 31, 2025Inventory
1.23BCNYFY2025 · Dec 31, 2025Accounts Payable
2.84BCNYFY2025 · Dec 31, 2025Short-term Debt
704.29MCNYFY2025 · Dec 31, 2025Other Current Liabilities
58.25MCNYFY2025 · Dec 31, 2025Long-term Debt
28.08MCNYFY2025 · Dec 31, 2025Common Stock (Book)
579.89MCNYFY2025 · Dec 31, 2025Retained Earnings
2.33BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.01BCNY448.36M · vs all stocks (USD)
52-Week Low
7.54CNYUpdated Aug 20, 202652-Week High
18.13CNYUpdated Aug 20, 202652-Week Change
24.18%vs all stocks
Beta
0.0390xvs all stocks
50-Day MA
9.10CNYUpdated Aug 20, 2026200-Day MA
10.47CNYUpdated Aug 20, 2026Avg 10-Day Volume
49.43MSharesUpdated Aug 20, 2026Avg 30-Day Volume
33.06MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.2500CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 21,155,815.331Operating Cash Flow (USD, TTM): 1,306,389.839
Financial Health
Altman Z-Score 3.31: safe zoneNotable
Altman Z-Score: 3.31
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $1.58B, above the global median of $520.53MNotable
Revenue (USD): 1,581,899,641.283Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
InMode Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
LB Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule